Fortress Biotech, Inc.
NASDAQ:FBIOBiotechnology
-$0.06 today
- Market cap
- $63.03M
- Beta
- 1.23
- P/E (TTM)
- 0.7
- EPS (TTM)
- $4.05
Volume 0.41M
Average 0.43M
FBIO Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Fortress Biotech, Inc.NASDAQ: FBIO
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow turns negative
Q1 FY2026 financing cash flow was -$27.39M, compared with $52.14M a year earlier. Trailing-twelve-month financing cash flow was -$2.09M. Over 3 fiscal years it compounded at +0.9% a year.
Context
- Financing cash flow amounted to 122.4% of revenue in FY2025, unchanged from a year earlier.
- Financing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly financing cash flow holds near -$27.39M or moves back toward the trailing-twelve-month quarterly average of -$522.75K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 77.44M USD
- Year-over-year change
- +9.6%
- 4-year CAGR
- -15.1%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 77.44M | +9.6% |
| FY2024 | 2024-12-31 | 70.64M | +115.8% |
| FY2023 | 2023-12-31 | 32.74M | -56.5% |
| FY2022 | 2022-12-31 | 75.32M | -49.4% |
| FY2021 | 2021-12-31 | 148.99M | — |
Financing Cash Flow vs competitors
How FBIO compares with its peers on the latest reported figures
- FBIO's LTM Mar 2026 financing cash flow of $2.09M is the 7th largest of the 10 companies compared; the peer median is $4.07M.
- Its year-over-year change of -102.2% is the lowest of 9, against a peer median of +85.0%.
- Financing cash flow amounts to 3.2% of revenue for FBIO, versus a peer median of 133.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $254.22M | +330054.5% | -11.9% | — | |
| LTM Mar 2026 | $250.14M | +95540.9% | +27.6% | — | |
| LTM Mar 2026 | $26.46M | +70.1% | — | — | |
| LTM Apr 2026 | $5.4M | +3417.5% | +223.2% | 299.7% | |
| LTM Mar 2026 | $4.07M | -89.4% | -37.6% | 1.6% | |
| LTM Jun 2024 | $2.15M | — | -37.1% | 264.1% | |
| LTM Mar 2026 | $2.09M | -102.2% | +0.9% | 3.2% | |
| LTM Mar 2026 | $495K | +53.3% | -19.2% | — | |
| LTM Mar 2026 | $189K | -99.9% | — | 2.1% | |
| LTM Mar 2026 | $0 | +100.0% | — | — | |
| Peer median (excluding FBIO) | $4.07M | +85.0% | -15.5% | 133.1% | |
Competitors are the stored peer set for FBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (164.83M) | (213.91M) | (154.15M) | (120.86M) | (32.92M) |
| Depreciation & Amortization | 6.79M | 9.35M | 6M | 4.46M | 4.66M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 19.49M | 22.99M | 17.03M | 32.62M | 28.74M |
| Change in Working Capital | 36.37M | (715K) | (12.52M) | (8.13M) | (25.1M) |
| Accounts Receivables | 834K | (4.84M) | 12.52M | 4.47M | (19.33M) |
| Inventory | (8.46M) | 1.74M | 3.95M | (4.23M) | 4.81M |
| Accounts Payables | 43.31M | 8.35M | (24.38M) | (6.39M) | (7.97M) |
| Other Working Capital | 690K | (5.97M) | (4.61M) | (1.98M) | (2.6M) |
| Other Non-Cash Items | (14.36M) | 2.89M | 15.42M | 11.71M | (41.17M) |
| Operating Cash Flow | (116.54M) | (179.4M) | (128.23M) | (80.19M) | (65.78M) |
| Capital Expenditures | (16.35M) | (3.06M) | (8.1M) | (15M) | 0 |
| Acquisitions (Net) | 56.86M | (20M) | 0 | 0 | 8.96M |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (11.78M) | (213K) | (2.04M) | 0 | 1.17M |
| Investing Cash Flow | 40.51M | (22.93M) | (2.1M) | (15M) | 10.12M |
| Debt Repayment | (9.64M) | 49.25M | (38.79M) | (7.33M) | (5.64M) |
| Common Stock Issued | 155.26M | 40.26M | 80.38M | 82.84M | 84.63M |
| Common Stock Repurchased | 0 | (1.11M) | 0 | 0 | (265K) |
| Dividends Paid | (8.78M) | (8.78M) | (8.77M) | (4.71M) | (664K) |
| Other Financing Activities | (4.8M) | (6.74M) | (529K) | (163K) | (360K) |
| Financing Cash Flow | 148.99M | 75.32M | 32.74M | 70.64M | 77.44M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 72.97M | (127.01M) | (97.59M) | (24.55M) | 21.79M |
| Free Cash Flow | (132.89M) | (182.46M) | (136.32M) | (95.19M) | (65.78M) |
Fortress Biotech, Inc.
NASDAQ:FBIO
Intrinsic Alpha fair value
Locked
Current Price
$1.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.